Integrated treatment of malignant bowel obstruction

doi:10.16689/j.cnki.cn11－9349/r.2019.04.006

PDF(785 KB)

Electronic Journal of Metabolism and Nutrition of Cancer ›› 2019, Vol. 6 ›› Issue (4) : 421-426. DOI: 10.16689/j.cnki.cn11－9349/r.2019.04.006

SHI Han-ping, CHEN Yong-bing, RAO Ben-qiang, WANG Kun-hua, CONG Ming-hua, LI Su-yi, CHEN Jun-qiang, BA Yi, SHU Yong-qian, SHEN lin, LI Wei, CHEN Zi-hua, JIANG Zhi-wei, LIU Ming, YU Shi-ying； Chinese Society of Nutrition Oncology

Author information +

1Department of Gastrointestinal Surgery/Clinical Nutrition, Beijing Shijitan Hospital/Capital Medical University Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition/Department of Oncology, Capital Medical University, Beijing 100038, China；2Department of Gastrointestinal and Hernia Surgery, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China；3Departments of General Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China；4Department of Nutrition and Metabolism Treatment of Cancer,Provincial Hospital Affiliated to Anhui Medical University, Hefei 230031,Anhui,China； 5Department of Gastrointestinal Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China； 6Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjins Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University, Tianjin 300060,China；7Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China；8Department of Gastroenterology, Beijing Cancer Hospital,Beijing 100142, China；9Cancer Center, the First Hospital of Jilin University, Changchun 130021, Jilin, China；10 Department of Gastrointestinal Surgery,Xiangya Hospital Central South University,Changsha 410008, Hunan, China；11Department of Gastrointestinal Surgery,Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing 210002, Jiangsu, China； 12Department of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China； 13Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China

Show less

History +

Abstract

Malignant bowel obstruction is a type of intestinal obstruction caused by a malignant tumor, most commonly seen in ovarian, gastric, and colorectal tumors. The pathophysiology of MBO is both similar and significantly different from that of intestinal obstruction caused by benign diseases. Despite the poor overall prognosis, MBO is not an incurable disease. The treatment of MBO is an integrated therapy that includes the following 11 aspects: inhibiting secretion, stopping vomiting, suppressing inflammation, controlling pain, fighting tumors, fluid management, promoting drainage, improving body energy, decompression and drainage, improving nutrition, and recanalization of intestinal cavities. MBO currently does not have a golden rule for all patients, nor does it have a master key that can solve all problems with certainty. The ideal MBO treatment can only be a comprehensive treatment on an individual basis. To form a cross major multi-disciplinary team of MBO diagnosis and treatment, formulate balance the ideal and the reality of MBO diagnostic standard, in order to solve the main contradiction, improve the quality of life as the guidance of treatment goals, fully listen to the opinions of the patient and family, and positive and effective comprehensive treatment can significantly improve the quality of life in patients with tumor and prolong survival time.

Key words

Tumor / Malignant intestinal obstruction / Comprehensive treatment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

SHI Han-ping, CHEN Yong-bing, RAO Ben-qiang, WANG Kun-hua, CONG Ming-hua, LI Su-yi, CHEN Jun-qiang, BA Yi, SHU Yong-qian, SHEN lin, LI Wei, CHEN Zi-hua, JIANG Zhi-wei, LIU Ming, YU Shi-ying； Chinese S. Integrated treatment of malignant bowel obstruction[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2019, 6(4): 421-426 https://doi.org/10.16689/j.cnki.cn11－9349/r.2019.04.006

References

1.Armas I, Brando M, Guerreiro I, et al. Incidental diagnosis of breast cancer in the pursuit of the treatment of intestinal obstruction. Autops Case Rep. 2019；9（1）:e2018071.
2.Ahmed M, Abbas H, Abdulsalam M, et al. Small bowel intussusception caused by metastatic melanoma: a case report.Cureus. 2019；11（7）:e5251.
3.Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR （long-acting octreotide acetate） for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther. 2003；17（3）:437-444.
4.Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol. 2012；83（3）:388-392.
5.Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage. 2007；34（1 Suppl）:S49-S59.
6.Mercadante S, Ripamonti C, Casuccio A, et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000；8（3）:188- 191.
7.Peng X, Wang P, Li S, et al. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 2015；13:50.
8.Ripamonti C, Twycross R, Baines M, et al； Working Group of the European Association for Palliative Care. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001；9（4）:223-233.
9.Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study.Lancet. 1985；2（8462）:990-993.
10.Fainsinger RL, Spachynski K, Hanson J, et al. Symptom control in terminally ill patients with malignant bowel obstruction （MBO）.J Pain Symptom Manage. 1994；9（1）:12-18.
11.Chen Q, Chen J, Hu B, et al. Submucosal injection of dexamethasone reduces postoperative discomfort after third-molar extraction: a systematic review and metas-analysis. J Am Dent Assoc. 2017；148（2）:81-91.
12.Atie M, Khoma O, Dunn G, et al. Gastrointestinal tract obstruction secondary to post-operative oedema: does dexamethasone administration help? J Surg Case Rep. 2016；2016（8）.pii:rjw139.
13.Laval G, Girardier J, Lassaunière JM, et al. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction? Palliat Med. 2000；14（1）:3-10.
14.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011；144（5）:646-674.
15.Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009；302（6）:649-658.
16.Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006；355（9）:885-895.
17.Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006；131（6）:1674-1682.
18.Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006；355（9）:873-884.
19.于世英, 沈琳, 江志伟, 等. 晚期癌症患者合并肠梗阻治疗的专家共识. 中华肿瘤杂志. 2007；29（8）:637-640.
20.Chouhan J, Gupta R, Ensor J, et al. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016；5（2）:239-247.
21.Paul Olson TJ, Pinkerton C, Brasel KJ, et al. Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review.JAMA Surg. 2014；149（4）:383-392.
22.Goto T, Takano M, Aoyama T, et al. Outcomes of palliative bowel surgery for malignant bowel obstruction in patients with gynecological malignancy.Oncol Lett. 2012；4（5）:883-888.
23.Medina-Franco H, García-Alvarez MN, Ortiz-López LJ, et al. Predictors of adverse surgical outcome in the management of malignant bowel obstruction.Rev Invest Clin. 2008；60（3）:212-216.
24.于恺英, 张骁玮, 潘磊,等. 老年患者快速康复6字法则. 肿瘤代谢与营养电子杂志. 2019；6（3）:273-276.
25.Gemlo B, Rayner AA, Lewis B, et al. Home support of patients with end-stage malignant bowel obstruction using hydration and venting gastrostomy. Am J Surg. 1986；152（1）:100-104.
26.Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.J Pain Symptom Manage. 2000；19（1）:23-34.
27.Nakajima N, Takahashi Y, Ishitani K. The volume of hydration in terminally ill cancer patients with hydration-related symptoms: a prospective study. J Palliat Med. 2014；17（9）:1037-1041.
28.Ceresoli M, Coccolini F, Catena F, et al. Water-soluble contrast agent in adhesive small bowel obstruction: a systematic review and meta-analysis of diagnostic and therapeutic value. Am J Surg. 2016；211（6）:1114-1125.
29.Syrmis W, Richard R, Jenkins-Marsh S, et al. Oral water soluble contrast for malignant bowel obstruction. Cochrane Database Syst Rev. 2018；3:CD012014.
30.Lee C, Vather R, OCallaghan A, et al. Validation of the phase II feasibility study in a palliative care setting: gastrografin in malignant bowel obstruction. Am J Hosp Palliat Care. 2013；30（8）:752-758.
31.Laneader A, Angelos P, Ferrell BR, et al. Ethical issues in research to improve the management of malignant bowel obstruction: challenges and recommendations. J Pain Symptom Manage. 2007；34（1 Suppl）:S20-S27.
32.Suo T, Gu X, Andersson R, et al. Oral traditional Chinese medication for adhesive small bowel obstruction. Cochrane Database Syst Rev. 2012；（5）:CD008836.
33.Gillis C, Buhler K, Bresee L, et al. Effects of nutritional prehabilitation, with and without exercise, on outcomes of patients who undergo colorectal surgery: a systematic review and meta-analysis. Gastroenterology. 2018；155（2）:391-410.
34.Song M, Chan AT. The potential role of exercise and nutrition in harnessing the immune system to improve colorectal cancer survival. Gastroenterology. 2018；155（3）:596-600.
35.Lilley EJ, Scott JW, Goldberg JE, et al. Survival, healthcare utilization, and end-of-life care among older adults with malignancy-associated bowel obstruction: comparative study of surgery, venting gastrostomy, or medical management. Ann Surg. 2018；267（4）:692-699.
36.Thampy S, Najran P, Mullan D, et al. Safety and efficacy of venting gastrostomy in malignant bowel obstruction: a systematic review.J Palliat Care. 2019:825859719864915.
37.Selby D, Nolen A, Sittambalam C, et al. Percutaneous transesophageal gastrostomy （PTEG）:A safe and well-tolerated procedure for palliation of end-stage malignant bowel obstruction. J Pain Symptom Manage. 2019；58（2）:306-310.
38.Sowerbutts AM, Lal S, Sremanakova J, et al. Home parenteral nutrition for people with inoperable malignant bowel obstruction. Cochrane Database Syst Rev. 2018；8:CD012812.
39.Cozzaglio L, Balzola F, Cosentino F, et al. Outcome of cancer patients receiving home parenteral nutrition. Italian Society of Parenteral and Enteral Nutrition （S.I.N.P.E.）.JPEN J Parenter Enteral Nutr. 1997；21（6）:339-342.
40.Obling SR, Wilson BV, Pfeiffer P, et al. Home parenteral nutrition increases fat free mass in patients with incurable gastrointestinal cancer. Results of a randomized controlled trial. Clin Nutr. 2019；38（1）:182-190.
41.Bozzetti F, Amadori D, Bruera E, et al. Guidelines on artificial nutrition versus hydration in terminal cancer patients. European Association for Palliative Care. Nutrition. 1996；12（3）:163-167.
42.Chen JH, Huang TC, Chang PY, et al. Malignant bowel obstruction: a retrospective clinical analysis. Mol Clin Oncol. 2014；2（1）:13-18.
43.Webster PJ, Aldoori J, Burke DA. Optimal management of malignant left-sided large bowel obstruction: do international guidelines agree? World J Emerg Surg. 2019；14:23.
44.Wang X, He J, Chen X, et al. Stenting as a bridge to resection versus emergency surgery for left-sided colorectal cancer with malignant obstruction: a systematic review and meta-analysis. Int J Surg. 2017；48:64-68.
45.Kagami S, Funahashi K, Ushigome M, et al. Comparative study between colonic metallic stent and anal tube decompression for Japanese patients with left-sided malignant large bowel obstruction.World J Surg Oncol. 2018；16（1）:210.
46.Lee YC, Jivraj N, Wang L, et al. Optimizing the care of malignant bowel obstruction in patients with advanced gynecologic cancer. J Oncol Pract. 2019:JOP1800793.